An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Inclusion Criteria:

- Completion of the core study is required for participation in the extension.

- 18 years of age or older

- World Health Organization (WHO) Performance Status score of: 0 - you are fully active
and more or less as you were before your illness; 1 - you cannot carry out heavy
physical work, but can do anything else; or 2 - you are up and about more than half
the day, you can look after yourself, but are not well enough to work.

- Life expectancy of 3 months or more

- Patients with measurable or evaluable disease who have histologically documented
advanced solid tumor and who have progressed after systemic therapy or for whom
standard systemic therapy does not exist

Exclusion Criteria:

- Severe and/or uncontrolled medical disease

- Known diagnosis of human immunodeficiency virus (HIV) infection

- Presence of any other active or suspected acute or chronic uncontrolled infection

- Severe cardiac insufficiency, with uncontrolled and/or unstable cardiac or coronary
artery disease

- History of another malignancy within 5 years prior to study entry, except for
curatively treated non-melanotic skin cancer or cervical cancer in situ

Other protocol-defined inclusion/exclusion criteria may apply.